Positron emission mammography effective in detecting breast cancer
Food and Drug Administration (FDA) officials in the United States have confirmed the presence of salmonella in a popular snack made by food giant Kellogg. The FDA says salmonella was found in a package of peanut butter sandwich crackers made by Kellogg as the company issued a precautionary recall across the food industry. The suspect
Full Post: Salmonella prompts recall of Kellogg’s snacks
A study has found that positron emission mammography (PEM), a new technique for imaging the breast, is not affected by either breast density or a woman’s hormonal status, two factors that limit the effectiveness of standard mammography and MRI at detecting cancer.
Results will be presented at the annual meeting of the Radiological Society of North America (RSNA).
“The ability of PEM to detect cancer does not appear to be adversely affected by breast density, hormone replacement therapy or menopausal status,” said lead researcher Kathy Schilling, M.D., director of breast imaging and intervention at the Center for Breast Care at Boca Raton Community Hospital in Florida. “The sensitivity of PEM is equal to or better than breast MRI, and PEM has fewer false-positive results.”
The ability of x-ray mammography, a standard screening tool for breast cancer, to detect lesions is reduced when performed on dense breasts, where tissue is less fatty and more glandular. Breast MRI is effective at detecting cancer in dense breasts and is increasingly being used to screen women at high risk for breast cancer. However, MRI has a high incidence of false-positive test results that indicate cancer is present when it is not. Researchers believe these false positives are due in part to hormonal changes that occur during a woman’s menstrual cycle.
“Unless the MRI is performed on day seven through 14 of a woman’s cycle, reading MRI images is extremely difficult,” Dr. Schilling said. “This is a significant problem with breast MRI.”
Because hormones do not have the same effect on PEM results, Dr. Schilling believes the imaging technique could play a significant role both in preoperatively evaluating breast cancer patients and in screening high-risk patients.
In the study, 208 patients with breast cancer underwent PEM, an application of high-resolution breast positron emission tomography (PET) in which a small amount of radioactive material is injected into the body to measure metabolic activity and determine the presence of disease. The researchers used a PET unit specially developed for the breast and small body parts to perform the PEM exam.
Of 189 malignant lesions imaged, PEM detected 176 for an overall sensitivity rate of 93 percent. Fifteen percent were ductal carcinoma in situ (DCIS), a noninvasive cancer confined to the ducts of the breast; 85 percent were invasive cancer.
PEM successfully detected cancer in 100 percent of fatty breasts, 93 percent of dense breasts, 85 percent of extremely dense breasts, 93 percent of women both with and without a history of hormone replacement therapy, 90 percent of pre-menopausal women and 94 percent of post-menopausal women.
According to Dr. Schilling, PEM is well tolerated by patients, who sit upright during the exam and are not alone or closely confined as they would be during an MRI exam. While breast MRI exams produce more than 2,000 images to be interpreted, PEM produces just 48 images that can be correlated with a woman’s mammogram.
“PEM is easier to use, easier to interpret and easier on the patients than MRI,” Dr. Shilling said.
“It is also ideal for those patients whose MRI is difficult to interpret due to hormonal influences, women with implants, patients with metal in their bodies, or patients who suffer from claustrophobia. It is exciting that we now have a functional imaging approach with high sensitivity that compliments our current anatomic imaging modalities,” she added.
A dual-headed dedicated gamma camera used during molecular breast imaging (MBI) can accurately detect small breast tumors less than 2 cm in size, according to a study performed at the Mayo Clinic in Rochester, MN. One-hundred fifty patients who had suspicious lesions smaller than 2 cm in size were imaged using dual-head molecular breast imaging.
Full Post: Dual-headed dedicated gamma camera accurately detects small breast tumors
Magnetic resonance imaging (MRI) alternated with mammography at six-month intervals can detect breast cancers not identified by mammography alone, a research team from The University of Texas M. D. Anderson Cancer Center will report at the 31st at the CRTC-AACR San Antonio Breast Cancer Symposium. MRI is known to be more sensitive in detecting breast
Full Post: Magnetic resonance imaging alternated with mammography may be best for high-risk women
Every day, women face a barrage of headlines about breast cancer. What should they do with all of that information? George Sledge, M.D., an internationally recognized breast cancer expert, pointed out that, despite all of the near-constant news and information about breast cancer, it is not the disease that impacts most women. “It’s important to
Full Post: Women need to be aware of changes, breast expert says
Breast-Specific Gamma Imaging (BSGI) is shown to be an effective method of identifying mammographically and clinically occult (hidden) breast cancer. BSGI is a molecular breast imaging technique that can see lesions independent of tissue density and discover very early stage cancers. According to findings presented today at the annual meeting of the Radiological Society of
Full Post: Breast-specific gamma imaging identifies hidden breast cancer
Breast-Specific Gamma Imaging (BSGI) has been proven to be a highly sensitive imaging technique for the diagnosis of invasive lobular carcinoma (ILC), a difficult to diagnose breast cancer. BSGI is a molecular breast imaging technique that can see lesions independent of tissue density and discover very early stage cancers. When compared to mammography, ultrasound and
Full Post: Molecular breast imaging technique shows greater sensitivity over mammography, ultrasound and MRI for difficult to diagnose breast cancer